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Elevated odds of metabolic syndrome 
in psoriasis: a population-based study 
of age and sex differences 
The authors of this study from Norway explain that evidence to 
date suggests an association between psoriasis and the meta-
bolic syndrome. They go on to explain that population-based 
studies including mild-to-severe cases, age and sex variation, 
and information on confounding factors are scarce. Their pop-
ulation-based study revealed that individuals reporting psoria-
sis displayed an elevated prevalence of metabolic syndrome. 
The strongest association they identified was in young women, 
where those with psoriasis had up to fourfold increased odds of 
metabolic syndrome, independent of lifestyle risk factors. The 
authors conclude that these results support a possible benefit 
from targeted screening for metabolic risk factors in all patients 
with psoriasis, irrespective of age and disease severity. Br J 
Dermatol 2015; 172: 419–427.
Vitiligo Area Scoring Index and Vitiligo 
European Task Force assessment: reliable 
and responsive instruments to measure 
the degree of depigmentation in vitiligo 
The authors of this study from the 
Netherlands explain that vitiligo is a com-
mon depigmenting skin disorder that can 
impair a patient’s quality of life. They go on 
to explain that there are no standardized 
outcome measures to assess the degree of 
depigmentation, and there is limited knowl-
edge on the measurement properties of 
outcome measures in vitiligo. Their study 
set out to assess the reliability and respon-
siveness of the Vitiligo Area Scoring Index 
(VASI) and the Vitiligo European Task Force 
assessment (VETFa), two well-described clinician-reported out-
comes. They studied three vitiligo patient groups. In one group 
of 31 patients, the interobserver reliability was assessed by three 
observers; in a second group of 27 patients the intraobserver 
reliability was assessed by two repeated measures by one of the 
observers; and in a third group of 33 patients, responsiveness of 
repigmentation was calculated ater 6 months of phototherapy 
and tested against hypotheses. The authors reported that in their 
hands VASI and VETFa were reliable and responsive instruments 
to assess the degree of depigmentation in patients with vitiligo. 
They concluded that VASI and VETFa are potential measurement 
instruments to assess the degree of depigmentation in vitiligo 
research. They finish with a word of caution: when used in indi-
vidual patient care, caution is needed when interpreting VASI 
and VETFa score changes because of the relatively large smallest 
detectible change. Br J Dermatol 2015; 172: 437–443. 
Heart rate safety profile for propranolol 
in children with infantile haemangioma 
In this study, Song and colleagues from Ningxia Medical 
University, Yinchuan, China studied the safety profile of divided 
doses of propranolol in the heart rate of children with infan-
tile haemangioma. They explain that heart rates are thought to 
decrease during propranolol treatment for infantile haeman-
gioma, but that no study has yet systematically characterized 
the changes in heart rates during long-term propranolol treat-
ment. Their study describes the careful and close monitoring of 
heart rate during 16 weeks of propranolol treatment in subjects 
with infantile haemangioma. They found that all heart rates 
were within the normal range and that a three-times-daily dos-
ing regimen had no significant effects on heart rates in patients 
with infantile haemangioma. They conclude that these results 
provide reassurance concerning the safety of using propranolol 
at 2 mg kg–1 per day with respect to infants’ heart rates for up to 
16 weeks of therapy. Br J Dermatol 2015; 172: 444–449.
Efficacy and safety of clindamycin 
phosphate 1.2% and benzoyl peroxide 
3.0% gel for the treatment of acne 
vulgaris in Japanese patients 
Kawashima and col-
leagues from Tokyo explain 
that a topical fixed-dose 
clindamycin phosphate 
1.2% and benzoyl per-
oxide 3.0% combination 
gel (CLNP/BPO 3.0%) is 
known to be both effective and safe in white people with acne. 
However, the authors state that the Japanese are perceived to 
have more sensitive skin than other ethnic groups. They there-
fore set out to evaluate the efficacy and safety of CLNP/BPO 
3.0% gel applied once or twice daily compared with CLNP 
1.2% applied twice daily in Japanese patients with acne. They 
recruited 800 patients who were randomized to receive CLNP/
BPO 3.0% once daily, CLNP/BPO 3.0% twice daily or CLNP 
twice daily for 12 weeks. Their primary end point was absolute 
change in the number of total lesions from baseline to week 12, 
to demonstrate the superiority of CLNP/BPO 3.0% twice daily 
and noninferiority of CLNP/BPO 3.0% once daily vs. CLNP 
twice daily. Their secondary end points were absolute and per-
centage changes in total lesions, inflammatory lesions, nonin-
lammatory lesions and Investigator’s Static Global Assessment 
score. Safety assessments included adverse events, laboratory 
tests, vital signs and local skin tolerability. Their results showed 
that the gel combination of clindamycin phosphate 1.2% with 
BPO 3.0% was an effective treatment with an acceptable safe-
ty and tolerability profile in Japanese patients with acne. Br J 
Dermatol 2015; 172: 494–503. 
